# US 2021/0079022 A1 · Heteroaryl plasma kallikrein inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079022 A1
- Document ID: US20210079022A1
- Status: Published application
- Kind: A1
- Application number: 17/024,189
- Filed: 2020-09-17
- Published: 2021-03-18
- Earliest claimed: 2019-09-18
- Assignees: Shire Human Genetic Therapies, Inc.
- Applicants: Shire Human Genetic Therapies, Inc.
- Inventors: Nikolaos Papaioannou; Jeremy Mark Travins; Sarah Jocelyn Fink; John Mark Ellard; Alastair Rae
- Web page: https://patentgrep.com/patent/US20210079022A1

## CPC

- A61P 29/02: without antiinflammatory effect
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt thereof,
wherein:
HetA is selected from a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyene having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, a 5- to 6-membered monocyclic heteroarylene having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, a 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclylene having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, and a 7- to 10-membered bicyclic heteroarylene having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur, wherein HetA is substituted with 0-4 RA groups;
each RA is independently selected from halogen, —CN, —C(R)═N(R), —C(O)R, —C(O)2R, —C(O)N(R)2, —NO2, —N(R)—N(R)2, —N(R)2, —N(R)C(O)R, —N(R)C(O)2R, —N(R)C(O)N(R)2, —N(R)S(O)2R, —OR, —OC(O)R, —OC(O)N(R)2, —SR, —S(O)R, —S(O)2R, —S(O)N(R)2, —S(O)2N(R)2, or an optionally substituted group selected from C1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur;
L is an optionally substituted C1-6 hydrocarbon chain, wherein 1-3 methylene units are independently replaced with -Cy-, —C(R)2— —O—, —NR—, —C(O)—, —S(O)2—, —C(O)NR—, —NRC(O)—, —S(O)2NR—, and —NRS(O)2—;
-Cy- is 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclylene, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclylene having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroarylene having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur;
R′ and R″ are independently selected from hydrogen, halogen, —OR, —NR2, —SR, and optionally substituted C1-6 aliphatic; wherein R′ may be taken together with a monocyclic HetA to form an optionally substituted fused 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclylene having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur;
R1, R2, R3, R4, R5, R6, R7, R8, and R9 are independently selected from hydrogen, halogen, —CN, —C(R)═N(R), —C(O)R, —C(O)2R, —C(O)N(R)2, —NO2, —N(R)—N(R)2, —N(R)2, —N(R)C(O)R, —N(R)C(O)2R, —N(R)C(O)N(R)2, —N(R)S(O)2R, —OR, —OC(O)R, —OC(O)N(R)2, —SR, —S(O)R, —S(O)2R, —S(O)N(R)2, —S(O)2N(R)2, or an optionally substituted group selected from C1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; and
each R is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur;
or two R groups on the same carbon or nitrogen are taken together with their intervening atoms to form a ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur, and 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur;
n is 0 or 1.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein when L is —(CR2)mNRC(O)— and m is 0 to 2 (e.g., 0 or 2), one of the following (a), (b), or (c) applies:
(a) n is 0;
(b) at least one of R5, R6, R7, R8, and R9 is CN; or
(c) R1 is an optionally substituted saturated monocyclic heterocycle comprising 1-3 nitrogen atoms, with the proviso that the compound is not N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-oxopyrrolidin-1-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-morpholinoimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-oxopyrrolidin-1-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-oxooxazolidin-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, or 4-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)morpholine-2-carboxylic acid.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein L is selected from the group consisting of-C(R)2NRC(O)-#, —C(R)2C(O)NRC(R)2-#, —C(R)2NRC(O)C(R)2-#, —C(R)2NRC(R)2-#, —C(R)2C(R)2NRC(R)2-#, —C(O)NRC(R)2-#, —C(R)2C(O)NR-#, —NRC(O)C(R)2-#, —CR2C(O)NRC(R)2-#, —SO2NRC(R)2-#, and —C(R)2NRSO2-#, wherein # represents the point of attachment to HetA.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein when L is —C(R)2NRC(O)-# or —C(R)2C(O)NR-#, one of the following (a), (b), or (c) applies:
(a) n is 0;
(b) at least one of R5, R6, R7, R8, and R9 is CN; or
(c) R1 is an optionally substituted saturated monocyclic heterocycle comprising 1-3 nitrogen atoms, with the proviso that the compound is not N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-oxopyrrolidin-1-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-morpholinoimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-oxopyrrolidin-1-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-oxooxazolidin-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, or 4-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)morpholine-2-carboxylic acid.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein the compound has a structure of Formula (I-a), Formula (I-b), Formula (I-c), Formula (I-d),
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein the compound has a structure of Formula (II):
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein the compound has a structure of Formula (II-a) or Formula (II-b):
or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein R′ is taken together with a monocyclic HetA to form an optionally substituted fused ring and the compound has a structure of Formula (III):
wherein Rfus is fused with HetA to form a fused 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclylene having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur,
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

The compound according to claim 1, wherein the compound has a structure of Formula (III-a) or Formula (III-b):
or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

The compound according to claim 1, wherein HetA is a 5-membered monocyclic heteroarylene having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, wherein HetA is substituted with 0-2 RA groups.

### Claim 11 (depends on 1)

The compound according to claim 1, wherein HetA is selected from:
wherein * represents to point of attachment to L.

### Claim 12 (depends on 1)

The compound according to claim 1, wherein a single instance of RA is C1-6 aliphatic substituted with halogen.

### Claim 13 (depends on 1)

The compound of claim 1, wherein the compound is any one of compounds I-1 through I-20, or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.

### Claim 15 (depends on 1)

A method of treating a plasma kallikrein-mediated disease or disorder using a compound of claim 1.

### Claim 16 (depends on 15)

The method of claim 15, wherein the disease or disorder is hereditary angioedema or diabetic macular edema.

### Claim 17 (depends on 1)

A method of treating hereditary angioedema or diabetic macular edema comprising administering to a patient in need thereof a compound of claim 1.
